Literature DB >> 350248

Intravenous labetalol in hypertensive patients given by fast and slow injection.

R M Pearson, C W Havard.   

Abstract

1 Labetalol reduces blood pressure when given by fast or slow intravenous injection. 2 The extent of the reduction in arterial pressure is independent of the rate of injection but the rate of fall of blood pressure can be controlled by varying the rate of injection. There is little effect on heart rate. 3 These observations suggest that labetalol possesses important advantages over other vasodilator hypotensive drugs in current use.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350248      PMCID: PMC1429349          DOI: 10.1111/j.1365-2125.1978.tb01645.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Side effects of diazoxide.

Authors:  G K Kumar; F C Dastoor; J R Robayo; M A Razzaque
Journal:  JAMA       Date:  1976-01-19       Impact factor: 56.272

2.  Angina-like syndrome with diazoxide therapy for hypertensive crisis.

Authors:  S A Kanada; D J Kanada; R A Hutchinson; D Wu
Journal:  Ann Intern Med       Date:  1976-06       Impact factor: 25.391

Review 3.  Hypertensive emergencies.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

4.  The importance of the rapid administration of diazoxide in accelerated hypertension.

Authors:  W J Mroczek; B A Leibel; M Davidov; F A Finnerty
Journal:  N Engl J Med       Date:  1971-09-09       Impact factor: 91.245

5.  Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

Authors:  J G Collier; N A Dawnay; C Nachev; B F Robinson
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

6.  Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.

Authors:  R M Pearson; C W Havard
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.

Authors:  B N Prichard; F O Thompson; A J Boakes; A M Joekes
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

8.  Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.

Authors:  P M Trust; E A Rosei; J J Brown; R Fraser; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

  9 in total
  4 in total

Review 1.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 2.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

Review 3.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

4.  Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings.

Authors:  R M Pearson; D N Griffith; M Woollard; I M James; C W Havard
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.